.Completing passions.R.S., M.S., H.G. and A.A.R. are actually planners of the 1M1M project. H.G. and also A.A.R. are panel of supervisors participants as well as R.S., M.S. and A.A.R. are actually members of the clinical advising board of N1C. A.A.R. reveals employment through LUMC, which has licenses on exon-skipping modern technology, a number of which has actually been licensed to BioMarin and ultimately sublicensed to Sarepta. As co-inventor of a few of these licenses, A.A.R. was entitled to a share of nobilities. A.A.R. further discloses functioning as ad hoc expert for PTC Rehabs, Sarepta Therapies, Regenxbio, Dyne Therapies, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and Astra Zeneca. Before 5 years, A.A.R. likewise performed speaking to for Alpha Anomeric. A.A.R. also discloses membership of the clinical boards of advisers of Eisai, Hybridize Therapeutics, Silence Therapeutics, Sarepta Rehabs, Sapreme and also Mitorx. In the past 5 years, A.A.R. was additionally a medical advisory board participant for ProQR. Wage for A.A.R. u00e2 s consulting and also encouraging tasks is actually paid out to LUMC. In the past 5 years, LUMC additionally got speaker honoraria coming from PTC Rehabs, Alnylam Netherlands, Italfarmaco and also Pfizer and also funding for contract research from Sapreme, Eisai, Galapagos, Synaffix and Alpha Anomeric. Project financing is actually obtained coming from Sarepta Therapies and Entrada via unconstrained grants. H.G. possesses absolutely nothing to reveal in relation to the subjects dealt with in this document. Previously 5 years, he has actually likewise acquired working as a consultant honoraria from UCB. M.S. obtained consultancy gratuity coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly and also Solaxa over the last 5 years, all unassociated to today composition. R.S. has nothing to reveal in connection with the subjects covered in this document. She has actually received speaker and/or consultancy gratuity or financing contributions coming from Abbvie, Bial, STADA and also Everpharma previously 5 years.